ATLANTA–A certain cytokine, or small protein that helps cells communicate during immune responses, can control whether immune cells promote or suppress inflammatory bowel disease, a finding that could lead to new treatments, according to a study led by Georgia State University.
Inflammatory bowel disease, chronic inflammation of all or part of the digestive tract, affects about 1.5 million Americans. The two main types, Crohn's disease and ulcerative colitis, develop from uncontrolled inflammation in the intestine, which can lead to severe diarrhea, pain, fatigue, weight loss and even death.
Researchers from Georgia State, Emory University and University of Michigan found the cytokine IL-36γ controls whether T cells, which play an active role in immune responses, become aggressive or suppressive. They discovered IL-36γ promoted the development of a specific type of T helper cell, Th9, which is associated with several diseases, including asthma, cancer and inflammatory bowel disease. The findings are published in the journal Mucosal Immunology.
"We were very intrigued whether the cytokine we were studying, IL-36γ, could be promoting intestinal inflammation through the development of these Th9 cells, and that's in fact what we found," said Dr. Tim Denning, lead author and associate professor in the Institute for Biomedical Sciences at Georgia State. "When we were discovering this, we also found it simultaneously inhibits a suppressive population of T cells termed regulatory T cells or Tregs, which are known to suppress inflammatory bowel disease."
"Our conclusions were that IL-36γ plays a critical role in driving the differentiation of pro-inflammatory Th9 cells and inhibiting the development of the suppressive Tregs. We think this can have major implications in the treatment of human inflammatory bowel disease, particularly ulcerative colitis, which has been shown to be associated with Th9 cells."
In a previous study, the researchers identified the cytokine IL-36γ as being highly expressed in the inflamed intestine of mice and humans. They found IL-36γ played a dual function, driving some of the pro-inflammatory process that aided in wound healing in inflammatory bowel disease.
The current study investigated the pro-inflammatory function of IL-36γ in mice to determine how IL-36γ functions in human inflammatory bowel disease. The researchers performed in vitro and in vivo experiments in mice.
In the future, the researchers will investigate how to block the ability of IL-36γ to bind to its receptor.
"If we can block the interaction of this cytokine with its receptor, we may be able to inhibit all of this cascade that we have defined and potentially develop a therapeutic for patients with inflammatory bowel disease, particularly ulcerative colitis," Denning said.
Co-authors of the study include Dr. Jian-Dong Li, Dr. Andrew Gewirtz, A. Harusato, H. Abo, V.L. Ngo, S.W. Yi and K. Mitsutake of Georgia State; S. Osuka and J.E. Kohlmeier of Emory University; and A. Nusrat of University of Michigan.
The study was funded by the National Institutes of Health and the Crohn's and Colitis Foundation.
To read the study, visit https://www.nature.com/mi/journal/vaop/ncurrent/full/mi201721a.html.
Story Source: Materials provided by Scienmag